In vitro generation of therapeutic noncytolytic T-cells by soluble polyoma TAA and Il-2.
Culture requirements for the optimal generation of polyoma-specific therapeutic lymphocytes by in vitro sensitization with soluble polyoma TAA were studied in bulk cultures of splenocytes from polyoma bearing mice. The acquisition of antipolyoma reactivity is connected with the creation of L3T4 positive, noncytolytic effector subpopulations, which dominated on the 9th day of stimulation of polyoma in vivo primed nonadherent splenocytes with TAA and 20 U/ml Il-2. Antipolyoma activity of effectors grown for 9 days with TAA and 200 U/ml Il-2 was accompanied by cytolytic activity. In both Il-2 concentrations the therapeutic reactivity faded similarly with time in spite of strong LAK-cell activity.
Ochalek
T
T
Centre of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow, Poland.
von Kleist
S
S
D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000276:immunology / Q000494:pharmacology*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000276:immunology; D051379:Mice; D008808:Mice, Inbred CBA; D011120:Polyomavirus; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*
D000952:Antigens, Polyomavirus Transforming; D007376:Interleukin-2; D011994:Recombinant Proteins